Esfam Biotech Pty Ltd
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Dose Escalation Phase 1 Study Evaluating the Safety and Pharmacokinetics of an Inhaled COVID-19 Inhibitor Delcetravir in Healthy Subjects (NCT05453279) | Esfam Biotech Pty Ltd | 2022-09-01 |
Track Esfam Biotech Pty Ltd automatically
Every clearance here is in the API, with alerts when new ones post.